These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 26212105)
1. Targeting the CD80/CD86 costimulatory pathway with CTLA4-Ig directs microglia toward a repair phenotype and promotes axonal outgrowth. Louveau A; Nerrière-Daguin V; Vanhove B; Naveilhan P; Neunlist M; Nicot A; Boudin H Glia; 2015 Dec; 63(12):2298-312. PubMed ID: 26212105 [TBL] [Abstract][Full Text] [Related]
2. Effect of administration of CTLA4-Ig as protein or cDNA on corneal allograft survival. Comer RM; King WJ; Ardjomand N; Theoharis S; George AJ; Larkin DF Invest Ophthalmol Vis Sci; 2002 Apr; 43(4):1095-103. PubMed ID: 11923251 [TBL] [Abstract][Full Text] [Related]
3. Interactions of CD80 and CD86 with CD28 and CTLA4. Ellis JH; Burden MN; Vinogradov DV; Linge C; Crowe JS J Immunol; 1996 Apr; 156(8):2700-9. PubMed ID: 8609386 [TBL] [Abstract][Full Text] [Related]
4. Modulation of cell cycle progression by CTLA4-CD80/CD86 interactions on CD4+ T cells depends on strength of the CD3 signal: critical role for IL-2. Mukherjee S; Ahmed A; Malu S; Nandi D J Leukoc Biol; 2006 Jul; 80(1):66-74. PubMed ID: 16624934 [TBL] [Abstract][Full Text] [Related]
5. ASP2408 and ASP2409, novel CTLA4-Ig variants with CD86-selective ligand binding activity and improved immunosuppressive potency, created by directed evolution. Oshima S; Karrer EE; Paidhungat MM; Neighbors M; Chapin SJ; Fan RA; Reed MA; Wu K; Wong C; Chen Y; Whitlow M; Anderson FA; Bam RA; Zhang Q; Larsen BR; Viswanathan S; Devens BH; Bass SH; Higashi Y Protein Eng Des Sel; 2016 May; 29(5):159-67. PubMed ID: 26968452 [TBL] [Abstract][Full Text] [Related]
6. Role of CD80, CD86, and CTLA4 on mouse CD4(+) T lymphocytes in enhancing cell-cycle progression and survival after activation with PMA and ionomycin. Mukherjee S; Maiti PK; Nandi D J Leukoc Biol; 2002 Nov; 72(5):921-31. PubMed ID: 12429713 [TBL] [Abstract][Full Text] [Related]
7. Affinity and cross-reactivity engineering of CTLA4-Ig to modulate T cell costimulation. Xu Z; Juan V; Ivanov A; Ma Z; Polakoff D; Powers DB; Dubridge RB; Wilson K; Akamatsu Y J Immunol; 2012 Nov; 189(9):4470-7. PubMed ID: 23018459 [TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive effect of ASP2408, a novel CD86-selective variant of CTLA4-Ig, in rats and cynomolgus monkeys. Oshima S; Fujii Y; Karrer EE; Takamura F; Chapin SJ; Neighbors M; Viswanathan S; Devens BH; Higashi Y; Mizuhara H Int Immunopharmacol; 2016 Nov; 40():310-317. PubMed ID: 27662596 [TBL] [Abstract][Full Text] [Related]
9. CTLA4-CD80/CD86 interactions on primary mouse CD4+ T cells integrate signal-strength information to modulate activation with Concanavalin A. Mukherjee S; Ahmed A; Nandi D J Leukoc Biol; 2005 Jul; 78(1):144-57. PubMed ID: 15788440 [TBL] [Abstract][Full Text] [Related]
10. CTLA4-Ig/CD86 interactions in cultured human endothelial cells: effects on VEGFR-2 and ICAM1 expression. Cutolo M; Montagna P; Soldano S; Contini P; Paolino S; Pizzorni C; Seriolo B; Sulli A; Brizzolara R Clin Exp Rheumatol; 2015; 33(2):250-4. PubMed ID: 25896473 [TBL] [Abstract][Full Text] [Related]
11. Expression of costimulatory molecules in the bovine corpus luteum. Cannon MJ; Davis JS; Pate JL Reprod Biol Endocrinol; 2007 Jan; 5():5. PubMed ID: 17266770 [TBL] [Abstract][Full Text] [Related]
12. CD28 interactions with either CD80 or CD86 are sufficient to induce allergic airway inflammation in mice. Mathur M; Herrmann K; Qin Y; Gulmen F; Li X; Krimins R; Weinstock J; Elliott D; Bluestone JA; Padrid P Am J Respir Cell Mol Biol; 1999 Oct; 21(4):498-509. PubMed ID: 10502560 [TBL] [Abstract][Full Text] [Related]